芳香化酶抑制剂在子宫肌瘤中的应用进展

子宫肌瘤是育龄期妇女最常见的良性肿瘤,治疗方法包括手术治疗和药物治疗,因其为雌激素依赖性肿瘤,绝大多数药物治疗理论均基于降低雌激素水平而达到缩小肌瘤的效果.芳香化酶抑制剂(AIs)可通过阻断雄烯二酮及睾酮向雌激素的转化,影响雌激素的生物合成,而降低体内雌激素水平.目前已有多项临床研究证实AIs在子宫肌瘤、转移性平滑肌瘤及预防促性腺激素释放激素激动剂(GnRHa)导致的不良反应方面的疗效.本研究旨在探讨芳香化酶在肌瘤组织中的表达及其对肌瘤生长的作用,对AIs在子宫肌瘤治疗中应用进行综述如下.

Application Progress of Aromatase Inhibitors for Uterine Fibroids

Uterine fibroids are the most common benign tumors in women during reproductive ages.Treatments for myomas include various types of surgical techniques and medical therapy.Most of the drugs shrink tumors by means of reducing the estrogen level based on the pathological mechanism that myoma growth is dependent on estrogen.Aromatase inhibitors(AIs) are developed to lower the synthesis of estrogen,in the light of blocking leiomyoma cells convert circulating androstenedione into estrone.Many clinical trials have demonstrated the effectiveness of AIs for uterine fibroids,benign metastasizing leiomyoma,and even flare effect on adverse reaction of gonadotropins.This article aims to review the current evidence about the expression of aromatase in leiomyoma tissues,its role in leiomyoma growth,and the therapeutic implications.